June 4, 2021 7:53am

News: Fate Therapeutics (FATE) introduced positive interim P1 data from the FT516 program for patients with relapsed / refractory B-cell lymphoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually June 4-8, 2021. FT516 is a universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells.

Pre-open indications: 4 BUYs: Adverum Biotechnologies (ADVM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Fate therapeutics (FATE); 2 SELLS: Homology Medicine (FIXX), Ionis Pharmaceuticals (IONS) and 1 Maintain SELL

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  


Dow futures are DOWN -0.05% (-19 points), S&P futures are UP +0.10% (+4 points) and NASDAQ futures are UP +0.17% (+23 points)

 

U.S. stock futures were down on Friday,

European stocks were higher,

Asia-Pacific stocks were mixed as the Reserve Bank of India held steady on interest rates.

 

Data Docket: Labor Department’s release of May’s nonfarm payrolls 8:30 a.m. ET report

 

Henry’omics:

The May jobs data will be a key factor in determining today’s session and the path of Fed policy in coming months …

Other than that, not much to look forward to, the oversold need a “stroke” to get back on/in the green.

  • Thursday, a hole sprung in the dike of sector share pricing, with a negative advance/decline line of 27/7 in the cell and gene therapy sector closing seriously negative;
  • Wednesday, a stake was driven into the heart of the sector with a negative advance/decline line of 10/23 in the cell and gene therapy sector closing seriously downward;
  • Tuesday opened positive at 18/15, 1 flat and 1 acquired, strayed neutral by the mid-day to 16/16, 2 flats and 1 acquired, closing positive at 17/16, 1 flat and 1 acquired.

It also helps to also “Review the month of May, last week:  there were 3 negative sector closes of five sessions (beginning 5/24) after the previous week’s) beginning 5/17) two negative closes of five sessions following the mid-month (5/10) four negative closes of five sessions as Monday began the month (5/3) with one negative close.”

  • Bottom line: May ended with 8 positive, 12 negative beginning June with 1 positive and 1 negative closes.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (32 – MESO added) to date …  https://www.regmedinvestors.com/articles/11628

 

Wednesday’s evening’s recap: “cell and gene therapy pricing action sprung a hole in the dike” … https://www.regmedinvestors.com/articles/11940

  • The Nasdaq closed DOWN -141.82 points (-1.03%);
  • The IBB closed down -0.13% and XBI closed down -0.38%
  • Sector volume was LOW with 1 of the 8-upside having higher than the 3-month average volume with the volume of 1 of 26-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.56 points or +3.20% at 18.04
  • Thursday’s percentage (%) of the 7-upside were +0.27% (SLDB) to +3.50% (QURE) while the 27-downside ranges from -0.25% (VSTM) to -5.97% (MESO);

Q2/21:

June: 1 positive and 2 negative close

May:  8 positive, 12 negative closes and 1 holiday

April: 10 positive and 11 negative closrs 

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell

Biostage (BSTG) closed flat with 3,528 shares traded after Wednesday’s -0.11 to $1.11 with 5,673 shares traded, Tuesday’s +$0.10 to $1.22 with 2216 shares traded post Monday’s holiday and last Friday’s -$0.20 to $1.12 with 4.372 shares traded.

Question#1:

Question#2: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications: BIG questions surround the day’s session as I am a bit disassociated toward the session on a Friday… however, keep your eyes on”

BUY:

Adverum Biotechnologies (ADVM)

CRISPR Therapeutics (CRSP)

Editas Medicine (EDIT)

 

SELL:

Homology Medicine (FIXX)

Ionis Pharmaceuticals (IONS)

 

The BOTTOM LINE: This is a confused sector as sentiment fades, momentum is usurped, fundamentals are being ignored – or is it a test of our staying power in certain equities.

I am STILL sticking with, “highs are in store” in the new month as constraints come-off many states and some companies re-open their doors to employees.

Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.